Key sentence from the paper: "The use of ADT is associated with an increased risk of hospitalisation for community-acquired pneumonia in men with prostate cancer.”

Key sentence from the paper: “… treatments with radiotherapy…and ADT…were each independently associated with increased risk of coronary heart disease, sudden cardiac death, fracture, and fracture requiring hospitalization.”

Key sentence from the paper: “Our study extends previous work supporting an association between use of ADT and Alzheimer disease and suggests that ADT may more broadly affect neurocognitive function.”

Key sentence from the paper: “The risk of [prostate cancer specific mortality] significantly decreased with the addition of ADT in the setting of high-dose [radiation therapy] for men with intermediate- or high-risk [prostate cancer] with a low, but not a high [competing mortality] score.”

Key sentence from the paper: “The role of serum [total testosterone] measurement during ADT remains unclear and here we have generated the hypothesis that [free testosterone] determination at 6-month is a better surrogate than [total testosterone] to predict [castrate-resistant prostate cancer] in patients with no metastatic disease.”

Key sentence from the paper: “…in men with known [coronary artery disease], only those with baseline low and lower 1/3 of the normal testosterone had a significantly higher [overall mortality] when they received ADT >6months compared with when they did not.”

Key sentence from the paper: “… for men with no or minimal comorbidity, it appears that the delivery of full versus dose-reduced [anti-androgens] was not associated with prolonged survival…suggesting that supplementing the LHRH agonist therapy with and [anti-androgen] for ~4 rather than 6 months may be sufficient to minimize death from [prostate cancer] and prolong survival as compared with no ADT use.”

Key sentence from the paper: “… Although large–scale RCTs are needed to ascertain the precise exercise prescription necessary to improve [metabolic syndrome] factors arising from ADT administration, patients can still benefit from consistent exercise as improvements in muscle mass, strength, physical function and psychological well-being have been demonstrated.”

Key sentence from the paper: “… we did not find any indication that second-line LHRH analogues resulted in further decrease in PSA even under equivalent low LH and testosterone levels prior to and after switching therapy.”

Key sentence from the paper: “[T]here appears to be an increased risk of death among AA [African American] men with low-risk or favorable intermediate-risk PC [prostate cancer] exposed to a short course of neoadjuvant ADT. Therefore, the use of ADT in AA men should be reserved for treating higher risk PC.”